LPX-TI641, Lapix Therapeutics‘ experimental oral therapy to restore immune system balance in people with multiple sclerosis (MS)…
Articles by Andrea Lobo, PhD
An artificial intelligence (AI)-based tool called Muse aims to accelerate drug development by optimizing clinical trial patient recruitment. The tool,…
Cionic has partnered with Lovell Government Services, a veteran-owned business, to expand veterans’ access to its Neural Sleeve,…
The MS Society of Canada is hosting its annual MS Read-a-Thon, a fundraiser where children are encouraged to…
Poltreg will receive a patent in China that covers the administration of its cell-based therapy PTG-007 for multiple sclerosis…
The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of…
Neufit is encouraging people with multiple sclerosis (MS) to register for its upcoming MS Bootcamp, a three-day event…
Treatment with rituximab, a CD20 inhibitor used off-label for multiple sclerosis (MS) patients, can stabilize disability progression and reduce…
Treatment with the investigational BTK inhibitor tolebrutinib significantly delayed the onset of confirmed disability progression in people with nonrelapsing…
Iaso Biotherapeutics has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials…
The National Multiple Sclerosis Society (NMSS) said it named Tim Coetzee, PhD, president and chief executive officer. Coetzee had…
Treatment with modafinil, a stimulant approved in the U.S. for treating certain sleep-related disorders, significantly reduced fatigue and improved overall…
The Australian government’s Medical Research Future Fund (MRFF) has awarded AU$2.9 million (about $1.96 million) to support a project focused…
Bit.bio, a company that creates human-derived cell products, has launched a novel product called ioAstrocytes, which provides functional…
The European Commission has approved a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) to treat adults with multiple…
Switching to one of the anti-CD20 targeting therapies Ocrevus (ocrelizumab) or rituximab may be an effective strategy for…
A large proportion of people with multiple sclerosis (MS) experience headaches as a result of their condition, and treatment…
Helius Medical Technologies said it has a booth at a meeting for multiple sclerosis (MS) professionals to showcase…
Progentos Therapeutics said it received $65 million in funding to support the development of myelin regeneration medications able to…
A higher intake of whole grain food is significantly associated with a lower likelihood of developing pediatric-onset multiple sclerosis…
A committee of the European Medicines Agency (EMA) is recommending the approval of a subcutaneous, or under-the-skin, formulation of…
NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by…
Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded…
A team of Kessler Foundation researchers has been granted more than $700,000 by the National Multiple Sclerosis Society for…
A clinical trial testing SpineX‘s Scone neuromodulation device for treating a neurogenic, or overactive, bladder, a common symptom of…
The prescribing label for Mavenclad (cladribine) in Great Britain has been extended to include the treatment of adults with…
Multiple sclerosis (MS) patients diagnosed in more recent years — specifically after 2017 — were more likely to start…
Getting the Bacillus Calmette-Guerin (BCG) vaccine to protect against tuberculosis (TB) or having latent (inactive) TB in young adulthood aren’t…
The U.S. Food and Drug Administration (FDA) has accepted SetPoint Medical, which is developing a nerve stimulator for people…
Lumina Imaging has partnered with the Multiple Sclerosis Association of America (MSAA) to provide affordable brain and spinal…